<?xml version="1.0" encoding="UTF-8"?>
<p>Antibodies can induce passive immunization for either prophylaxis or therapy. The S protein is considered as a potential candidate vaccine target, where the formed antibodies against S protein could block receptor binding and entry of CoV into the cells [
 <xref rid="B6" ref-type="bibr">6</xref>,
 <xref rid="B88" ref-type="bibr">88</xref>,
 <xref rid="B89" ref-type="bibr">89</xref>]. Sui 
 <italic>et al.</italic> identified and produced 80R, a neutralizing human monoclonal antibody, which is able to inhibit SARS-CoV entry via preventing S1 binding to ACE2 receptors [
 <xref rid="B20" ref-type="bibr">20</xref>]. Moreover, neutralizing human monoclonal antibodies against SARS-CoV-2 can be produced by using a soluble form of its binding receptor (ACE2) combined with an immunoglobulin Fc domain, allowing the development of long-lasting immunity against the virus [
 <xref rid="B48" ref-type="bibr">48</xref>].
</p>
